Liantao Guo, Yan Rao, Yawen Song, Jiawei Hu, Zixuan Luo, Shengrong Sun, Chuang Chen, Deguang Kong
{"title":"SIX1通过ZEB1/IL6/STAT3信号轴传递乳腺癌进展信号。","authors":"Liantao Guo, Yan Rao, Yawen Song, Jiawei Hu, Zixuan Luo, Shengrong Sun, Chuang Chen, Deguang Kong","doi":"10.1038/s41388-025-03499-6","DOIUrl":null,"url":null,"abstract":"Epithelial-mesenchymal transition (EMT) and breast cancer stem cells (BCSCs) are pivotal in breast cancer mechanism research. It was demonstrated that Sine oculis homeobox homolog 1 (SIX1) orchestrates breast cancer EMT and BCSCs, concurrently activating the Signal transducer and activator of transcription 3 (STAT3) signaling pathway. Yet, the mechanism by which SIX1 modulates STAT3 and its potential to regulate EMT and BCSCs through STAT3 signaling remain unexplored. Here, cellular, animal, organoid models, and integrated single-cell transcriptomic and ST-seq of human breast cancer specimens were conducted. The results revealed that SIX1 can enhance Zinc finger E-box binding homeobox 1 (ZEB1) expression and translation, which in turn binds to the Interleukin-6 (IL6) promoter (1138bp–1148bp) to stimulate its transcription, translation, and secretion. Subsequently, IL6 can activate the cell’s own STAT3 signaling pathway, promote the phosphorylation of STAT3, promote the downstream signal c-Myc and Cyclin D1 transduction, and promote the expression of stem cell-related transcription factors such as ALDH1A1, OCT4, and SOX2, thereby promoting EMT and stemness. In addition, this study found a new cell interaction model, in which the above-mentioned secreted IL6 can promote the activation of STAT3 signaling pathway, EMT and stemness transformation in the surrounding cells with low expression of SIX1 in a paracrine manner. Our data favored that SIX1/ZEB1/IL6 axis activated the STAT3 signaling pathway of the breast cells themselves and surrounding cells with low SIX1 expression, thus promoting EMT and stemness transformation, activating the malignant progression of the whole breast cancer.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"44 37","pages":"3493-3511"},"PeriodicalIF":7.3000,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41388-025-03499-6.pdf","citationCount":"0","resultStr":"{\"title\":\"SIX1 transmits signals for breast cancer progression via the ZEB1/IL6/STAT3 signaling axis\",\"authors\":\"Liantao Guo, Yan Rao, Yawen Song, Jiawei Hu, Zixuan Luo, Shengrong Sun, Chuang Chen, Deguang Kong\",\"doi\":\"10.1038/s41388-025-03499-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Epithelial-mesenchymal transition (EMT) and breast cancer stem cells (BCSCs) are pivotal in breast cancer mechanism research. It was demonstrated that Sine oculis homeobox homolog 1 (SIX1) orchestrates breast cancer EMT and BCSCs, concurrently activating the Signal transducer and activator of transcription 3 (STAT3) signaling pathway. Yet, the mechanism by which SIX1 modulates STAT3 and its potential to regulate EMT and BCSCs through STAT3 signaling remain unexplored. Here, cellular, animal, organoid models, and integrated single-cell transcriptomic and ST-seq of human breast cancer specimens were conducted. The results revealed that SIX1 can enhance Zinc finger E-box binding homeobox 1 (ZEB1) expression and translation, which in turn binds to the Interleukin-6 (IL6) promoter (1138bp–1148bp) to stimulate its transcription, translation, and secretion. Subsequently, IL6 can activate the cell’s own STAT3 signaling pathway, promote the phosphorylation of STAT3, promote the downstream signal c-Myc and Cyclin D1 transduction, and promote the expression of stem cell-related transcription factors such as ALDH1A1, OCT4, and SOX2, thereby promoting EMT and stemness. In addition, this study found a new cell interaction model, in which the above-mentioned secreted IL6 can promote the activation of STAT3 signaling pathway, EMT and stemness transformation in the surrounding cells with low expression of SIX1 in a paracrine manner. Our data favored that SIX1/ZEB1/IL6 axis activated the STAT3 signaling pathway of the breast cells themselves and surrounding cells with low SIX1 expression, thus promoting EMT and stemness transformation, activating the malignant progression of the whole breast cancer.\",\"PeriodicalId\":19524,\"journal\":{\"name\":\"Oncogene\",\"volume\":\"44 37\",\"pages\":\"3493-3511\"},\"PeriodicalIF\":7.3000,\"publicationDate\":\"2025-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.comhttps://www.nature.com/articles/s41388-025-03499-6.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncogene\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41388-025-03499-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogene","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41388-025-03499-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
SIX1 transmits signals for breast cancer progression via the ZEB1/IL6/STAT3 signaling axis
Epithelial-mesenchymal transition (EMT) and breast cancer stem cells (BCSCs) are pivotal in breast cancer mechanism research. It was demonstrated that Sine oculis homeobox homolog 1 (SIX1) orchestrates breast cancer EMT and BCSCs, concurrently activating the Signal transducer and activator of transcription 3 (STAT3) signaling pathway. Yet, the mechanism by which SIX1 modulates STAT3 and its potential to regulate EMT and BCSCs through STAT3 signaling remain unexplored. Here, cellular, animal, organoid models, and integrated single-cell transcriptomic and ST-seq of human breast cancer specimens were conducted. The results revealed that SIX1 can enhance Zinc finger E-box binding homeobox 1 (ZEB1) expression and translation, which in turn binds to the Interleukin-6 (IL6) promoter (1138bp–1148bp) to stimulate its transcription, translation, and secretion. Subsequently, IL6 can activate the cell’s own STAT3 signaling pathway, promote the phosphorylation of STAT3, promote the downstream signal c-Myc and Cyclin D1 transduction, and promote the expression of stem cell-related transcription factors such as ALDH1A1, OCT4, and SOX2, thereby promoting EMT and stemness. In addition, this study found a new cell interaction model, in which the above-mentioned secreted IL6 can promote the activation of STAT3 signaling pathway, EMT and stemness transformation in the surrounding cells with low expression of SIX1 in a paracrine manner. Our data favored that SIX1/ZEB1/IL6 axis activated the STAT3 signaling pathway of the breast cells themselves and surrounding cells with low SIX1 expression, thus promoting EMT and stemness transformation, activating the malignant progression of the whole breast cancer.
期刊介绍:
Oncogene is dedicated to advancing our understanding of cancer processes through the publication of exceptional research. The journal seeks to disseminate work that challenges conventional theories and contributes to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers. Emphasis is placed on research shedding light on processes driving metastatic spread and providing crucial insights into cancer biology beyond existing knowledge.
Areas covered include the cellular and molecular biology of cancer, resistance to cancer therapies, and the development of improved approaches to enhance survival. Oncogene spans the spectrum of cancer biology, from fundamental and theoretical work to translational, applied, and clinical research, including early and late Phase clinical trials, particularly those with biologic and translational endpoints.